Curis (NASDAQ:CRIS) Stock Rating Reaffirmed by HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $26.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 106.35% from the stock’s previous close.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Curis in a report on Wednesday.

Curis Trading Down 3.1 %

NASDAQ:CRIS opened at $12.60 on Wednesday. The firm’s fifty day simple moving average is $13.60 and its 200 day simple moving average is $11.44. Curis has a twelve month low of $3.80 and a twelve month high of $18.53.

Curis (NASDAQ:CRIS) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.11). Curis had a negative net margin of 486.45% and a negative return on equity of 224.75%. The company had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $2.31 million. During the same quarter in the prior year, the firm earned ($2.40) EPS. On average, analysts expect that Curis will post -5.39 EPS for the current year.

Institutional Trading of Curis

Institutional investors have recently modified their holdings of the company. CM Management LLC increased its holdings in Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after buying an additional 95,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the period. Focused Wealth Management Inc raised its holdings in shares of Curis by 79.2% during the first quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 14,656 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in Curis during the first quarter valued at $219,000. Finally, a16z Perennial Management L.P. purchased a new stake in Curis in the fourth quarter valued at $85,000. 29.97% of the stock is currently owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.